rev:  May 25, 2005

HOME (index page)

Return (alphabetical antibody page)

Return  (cytokeratin data page)


(anti-Human and others as indicated)

RDI Divison of researchd Industries Intl  offers a wide line of  antibodies. Since no one antibody works best for all applications (neutralization, blotting, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.


Mab to Tenascin

cat#RDI-TENASNabm    $438.00/100ug      

      RDI-TENASNabmX  $688.00/200ug

Clone T2H5

Category Mouse monoclonal

Form :purified IgG

Ig Class IgG1

Antigen Isolated from human mammary tumor cells

Introduction Tenascin is a large hexameric extracellular matrix molecule with oncofetal properties. During embryonic development the protein is expressed in many parenchymatous organs, where it appears to have a regulating role in epithelial differentiation. In most mature tissues the expression is restricted to the papillary dermis, but reappears in tissue regeneration and repair and in neoplasia. In basal cell carcinoma two forms (Mr 210,000 and 300,000 kDa) of tenascin can be found, in contrast to normal skin and fibroblasts, where one form predominantly exists (Mr 300,000 kDa).

Clinical Application/Specificity Detects extracellular matrix glycoprotein Tenascin in connection with gliomas, mammary tumors and in proliferative skin diseases (psoriasis, skin tumors)

Recommended for 1: 5 - 1:20

Application :RIA, ELISA

                  :Immunoblotting (Western)

                 : Immunohistochemistry

                 : Suitable for frozen sections

                  :parrafin sections (with high temperature unmasking)

Antigen Recognized in species tested so far: Human

Working Dilution : 2-4ug/ml

Dilution Buffer PBS (1% BSA and 0.09% Na-Azide)

Incubation Time 1 h at RT

Storage At 4°C

Volume : 100ug


A.A. Verstraeten, E.J. Mackie, Ph.C. Hageman, J. Hilgers, D.J. Schol, G.J. De Jongh and J. Schalkwijk: Tenascin expression in basal cell carcinoma. British Journal of Dermatology (1992) 127, 571-574.

Bosman, F.T. et al. Progr Histochem, Cytochem 24(4) 1-92 (1992)

Koukoulis, G.K. et al, Human Pathol., 222,, 636-643 (1991)

For research use only. Not supplied for use in human diagnostic or therapeutic procedures

RDI div of researchd Industries Intl

(Research Diagnostics Inc)

San Jose, 95123 CA Snell ave 658


phone 408-780-0908

      or (978) 371-6446 or 408-780-0908

fax   408-780-0908


RETURN(cytokeratin page)